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PEMBANGUNAN DAN PENILAIAN TABLET TERKECAI ORAL 
TERLINDUNG RASA UNTUK SATU DRUG LARUT AIR, SUMATRIPTAN 
SUKSINAT DAN SATU DRUG TIDAK LARUT AIR, ONDANSETRON 
 
ABSTRAK 
 
Tujuan penyelidikan ini dijalankan adalah untuk menformulasikan tablet terkecai 
oral terlindung rasa (ODTs) ordansetron (tidak larut air) dan sumatriptan suksinat 
(larut air) menggunakan teknologi-teknologi berlainan yang sedia ada iaitu Orasolv, 
pengeringan sejuk beku dan Wowtab. Dalam teknik Wowtab dan pengeringan sejuk 
beku, rasa pahit ordansetron telah dilindungi dengan penambahan suatu pemanis 
(aspartam), manakala dalam teknik Orasolv melalui pengkompleksan drug dengan 
Eudragit EPO (1:0.5). Dalam kesemua teknik yang digunakan untuk penyediaan 
ODTs sumatriptan suksinat, rasa drug yang sangat pahit telah dilindungi melalui 
penyalutan dengan Eudragit EPO (1:1) menggunakan kaedah pengeringan semburan. 
Dalam teknik Wowtab, formulasi ordansetron dan sumatriptan suksinat telah 
disediakan menggunakan jenis dan kepekatan superdisintegran yang berbeza. Teknik 
Wowtab dan pengeringan sejuk beku menghasilkan formulasi tablet ordansetron 
yang optimum dengan masa pengecaian in vitro dan kandungan air menepati syarat 
USP iaitu masing-masing < 10 saat dan <4%. Namun, tiada formulasi ordansetron 
yang disediakan melalui teknik Orasolv menepati syarat-syarat rasmi untuk masa 
pengecaian in vitro. Sebaliknya, ketiga-tiga teknik (Orasolv, pengeringan sejuk beku 
dan Wowtab) telah menghasilkan formulasi sumatriptan suksinat optimum yang 
memenuhi syarat rasmi USFDA untuk masa pengecaian in vitro selama <60 saat. 
Profil pelepasan in vitro untuk formulasi yang optimum bagi kedua-dua drug adalah 
setanding dengan produk komersial. Formulasi optimum bagi ordansetron dan 
sumatriptan suksinat yang disediakan menggunakan teknik Wowtab telah dipilih 
untuk penilaian rasa, perasaan di dalam mulut dan masa pengecaian in vivo 
 xliv
menggunakan sukarelawan-sukarelawan manusia. Formulasi ordansetron dan 
sumatriptan suksinat yang optimum mempunyai rasa yang sedap, perasaan di dalam 
mulut yang bagus dan mengecai di dalam mulut dalam masa, masing-masing 12 dan 
41 saat. Tambahan pula, kedua-dua formulasi yang optimum adalah stabil untuk 
sekurang-kurangnya 6 bulan pada 40 °C/75% RH dan 25 °C/65% RH. Formulasi 
ordansetron yang optimum terdiri daripada poliplasdon XL-10 (15%), aspartam (7%) 
dan perisa strawberi (1%) manakala sumatriptan suksinat mengandungi Kollidon CL-
SF (5%), ammonium bikarbonat (10%), aspartam (2%) dan perisa nanas (0.75%). 
Dua kaedah HPLC isokratik yang spesifik dan sensitif untuk penentuan ondansetron 
dan sumatriptan suksinat dalam plasma telah dibangunkan dan divalidasi secara 
berasingan. Keputusan berselang kerpercayaan 90% bagi Cmax dan AUC0-∞ yang 
didapati daripada ujian biokeperolehan menunjukkan bahawa kadar dan tahap 
penyerapan formulasi Rujukan dan Ujian bagi ondansetron dan sumatriptan suksinat 
adalah biosetara. Kesimpulannya, ODTs ordansetron dan sumatriptan suksinat 
terlindung rasa telah disediakan dengan jayanya dan mungkin berguna sebagai 
alternatif kepada produk-produk komersial yang sedia ada.  
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DEVELOPMENT AND EVALUATION OF TASTE MASKED ORALLY 
DISINTEGRATING TABLETS OF A WATER SOLUBLE DRUG, 
SUMATRIPTAN SUCCINATE AND A WATER INSOLUBLE DRUG, 
ONDANSETRON 
 
 
ABSTRACT 
 
 
The aim of the present research was to formulate taste masked orally disintegrating 
tablets (ODTs) of ondansetron (water insoluble) and sumatriptan succinate (water 
soluble) using different available technologies namely Orasolv, freeze drying and 
Wowtab. In Wowtab and freeze drying techniques, the bitter taste of ondansetron 
was masked by the addition of a sweetener (aspartame), whereas in the Orasolv 
technique by complexing the drug with Eudragit EPO (1:0.5). In all the techniques 
used to prepare sumatriptan succinate ODTs, the intensely bitter taste of the drug was 
masked by coating it with Eudragit EPO (1:1) using spray dryer. In Wowtab 
technique, ondansetron and sumatriptan succinate formulations were prepared using 
different types and concentrations of superdisintegrants. The Wowtab and freeze 
drying techniques produced optimized formulations of ondansetron tablets with an in 
vitro disintegration time and water content within the USP requirement of ≤10 sec 
and ≤4%, respectively.  However, none of the ondansetron formulations prepared by 
Orasolv technique met the official requirements for in vitro disintegration time. On 
the other hand, the three techniques (Orasolv, freeze drying and Wowtab) produced 
optimized formulations of sumatriptan succinate that fulfilled the USFDA official 
requirements for in vitro disintegration time of <60 sec. The in vitro release profiles 
of the optimized formulations for the two drugs were comparable with the 
commercial products. The optimized formulations of ondansetron and sumatriptan 
succinate prepared by Wowtab technique were selected for the evaluation of taste, 
mouth feel and in vivo disintegration time using human volunteers. The optimized 
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formulations of ondansetron and sumatriptan succinate had a pleasant taste with good 
mouth feel and disintegrated in the mouth within 12 and 41 sec, respectively. In 
addition, both optimized formulations were stable for at least 6 months at 40 °C/75% 
RH and 25 °C/65% RH. The optimized formulation of ondansetron consisted of 
Polyplasdone XL-10 (15%), aspartame (7%) and strawberry flavour (1%) whereas 
sumatriptan succinate consisted of Kollidon CL-SF (5%), ammonium bicarbonate 
(10%), aspartame (2%) and pineapple flavour (0.75%). Two specific and sensitive 
isocratic HPLC methods for the determination of ondansetron and sumatriptan in 
plasma were developed and validated separately. The 90% confidence interval results 
of Cmax and AUC0-∞ obtained from the bioavailability studies demonstrated that 
Reference and Test formulations of ondansetron and sumatriptan succinate are 
bioequivalent in their rate and extent of absorption. In conclusion, taste masked 
ondansetron and sumatriptan succinate ODTs were successfully prepared and could 
be useful alternatives to commercially available products. 
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CHAPTER 1 
 
INTRODUCTION 
 
1.1 Introduction 
The most important route for drug delivery is undoubtedly the oral route which has a 
wide acceptance and accounts up to 50-60% of total dosage forms. Drugs that are 
administered orally, solid oral dosage forms in general and tablets in particular, 
represent the preferred class of product. This is due to the convenience in self 
administration, compactness, ease of manufacturing, accurate dosage, pain avoidance 
and most importantly patient compliance afforded by those dosage forms (Bhowmik 
et al., 2009; Bharawaj et al., 2010). One important drawback of this dosage form is 
that some patients who suffer from dysphagia (difficulty in swallowing) cannot take 
their medication as prescribed by their doctor, resulting in a high incidence of non-
compliance and therapy failure. A survey conducted in Norway revealed that 26% 
out of 6158 patients experienced difficulty in swallowing conventional tablets due to 
their large size and taste of the tablets (Anderson et al., 1995; Frijlink, 2003; 
Chandrasekhar et al., 2009). This difficulty is common among all age groups and 
more specific with paediatric, geriatric and bedridden or disabled patients and also 
patients with persistent nausea and vomiting, those who are travelling and those who 
have little or no access to water (Seager, 1998; Wagh et al., 2010). For example, a 
very elderly patient may not be able to swallow a daily dose of antidepressant due to 
hand tremors and dysphagia. An eight year-old child with allergies has difficulty in 
ingesting anti-histamine syrup due to the underdeveloped muscular and nervous 
system and desires for a more convenient dosage form than syrup. An 
institutionalised schizophrenic patient can hide a conventional tablet under the 
tongue to avoid his/her daily dose of an atypical antipsychotic. A middle aged 
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woman undergoing radiation therapy for breast cancer may be too nauseous to 
swallow H2-blocker (Hirani et al., 2009; Prajapati and Ratnakar, 2009). A migraine 
patient who is travelling with little or no access to water may not be able to consume 
the conventional tablet due to the risk of choking. Hence, development of a patient 
friendly solid oral dosage form that disintegrate/dissolve rapidly in the mouth when 
in contact with saliva has attracted substantial attention in both academia and 
industry in order to address swallowing difficulties  associated with the conventional 
solid oral dosage forms (Sastry et al., 2000; AlHusban et al., 2010a). This dosage 
form is commonly referred to as orally disintegrating tablets (ODTs) which are a 
perfect fit for all the patients aforementioned.  
 
United States Food and Drug Administration (USFDA) defined ODT as “A solid 
single unit dosage form containing active ingredient which disintegrates rapidly 
usually within a matter of seconds when placed upon the tongue (USFDA, 2008).” 
The disintegration time for ODTs generally ranges from several seconds to about a 
minute (Bandari et al., 2008). European Pharmacopoeia adopted the term 
‘orodispersible tablets’ for tablets that disperse/disintegrate rapidly in the mouth 
before being swallowed and which should disintegrate within 3 min (European 
Pharmacopoeia, 2002). These tablets are also called as quick disintegrating tablets, 
mouth dissolving tablets, fast disintegrating tablets, fast dissolving tablets, rapid 
dissolving tablets, melt-in-mouth tablets, porous tablets and repimelts. All of these 
terms were approved by United States Pharmacopoeia (USP 30, 2007). 
 
 
Recent market surveys indicate that more than half of the patient population prefer 
ODTs to other dosage forms and most consumers would ask their doctors for ODTs 
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(70%), purchase ODTs (70%), or prefer ODTs to regular tablets or liquids (>80%) 
(Brown, 2001; Deepak, 2004). These responses may be attributed to the ODT 
advantages such as ease of administration, ease of swallowing, pleasant taste and the 
availability in several flavours (Seager, 1998). ODTs also offer clinical advantages 
such as improved safety (risk of choking or suffocation due to physical obstruction 
with oral administration of conventional tablets is avoided) and, in some cases, 
improved efficacy (increased bioavailability of drugs that are absorbed from mouth, 
pharynx and oesophagus). In addition, several business needs are driving ODT 
technology development and the commercialization of new products such as the need 
for expanded product lines, improved life-cycle management, extended patent life, 
and marketing advantages (Seager, 1998; Brown, 2001). The summary of ODT 
products available in the market are listed in Table 1.1.  
 
 
Table 1.1: Summary of commercially available ODT products. 
 
Trade name Active ingredient Category Manufacturer 
Abilify Discmelt Aripiprazole Antipsychotic Bristol-Myers Squibb 
Alavert Loratadine Antihistamine Wyeth 
Aricept ODT Donepezil HCl Cholinomimetic Eisai and Pfizer 
Benadryl Fastmelt Diphenhydramine Anticholinergic Pfizer 
Benadryl Allergy 
& Sinus Fastmelt 
Diphenhydramine & 
pseudoephedrine 
Anticholinergic 
and antiallergic Pfizer 
Benadryl Fastmelt Diphenhydramine & 
pseudoephedrine 
Anticholinergic 
and antiallergic Warner Lambert 
Children’s 
Dimetapp ND Loratadine Antihistamine Wyeth 
Cibalginadue Fast Ibuprofen NSAID Novartis 
Claritin RediTabs Loratadine Antihistamine Schering Plough 
Clarinex RediTabs Desloratadine Antihistamine Schering Plough 
Domray MD Domperidone Antiemetic Ray Remedies 
Excedrin Quick 
Tabs Acetaminophen 
Analgesic and 
antipyretic Bristol-Myers Squibb 
Fazalco Clozapine Antipsychotic Alamo Pharmaceuticals 
Febrectol Paracetamol Analgesic and antipyretic Prographarm 
Feldene Melt Piroxicam NSAID Pfizer 
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Table 1.1: continued…… 
 
Fluoxetine ODT Fluoxetine Antidepressant Bioavail 
Gaster D Famotidine Anti ulcer Yamanouchi 
Hyoscyamine 
sulfate ODT Hyoscyamine sulfate Anticholinergic ETHEX Corporation 
Imodium Instant 
melts Loperamide HCl Antidiarrheal Janssen 
Kemstro Baclofen Muscle relaxant Schwarz Pharma 
Klonopin Wafers Clonazepam Antiepileptic Roche 
Kid Relief Acetaminophen Analgesic and antipyretic Ethypharm 
Maxalt-MLT Rizatriptan Benzoate Antimigraine Merck 
Mosid MT Mosapride Prokinetic Torrent 
Nimulid MD Nimesulide NSAID Panacea Biotech 
Nasea OD Ramosetoron Antiemetic Yamanouchi 
NuLev Hyoscyamine sulfate Anticholinergic Schwarz Pharma 
Nurofen Flash Tab Ibuprofen NSAID Boots Healthcare 
Orapred ODT Prednisolone Corticosteroid Sciele Pharma 
Pepcid ODT Famotidine Antiulcer Janssen 
Permax Pergolide Antiparkinson Amarin Corporation 
Propulsid 
Quicksolv 
Cisapride 
monohydrate Prokinetic Janssen 
Ralivia Flashdose Tramadol HCl Opioid analgesic Bioavail 
Rapimelt Zolmitriptan Antimigraine Astra Zeneca 
Remeron SolTab Mirtazapine Antidepressant Organon Inc 
Risperidal M-Tab Risperidone Antipsychotic Janssen 
Rofaday MT Rofecoxib Antiinflammatory Lupin 
Romilast Montelukast Antiasthma Ranbaxy 
Tempra Quicklets Acetaminophen Analgesic and antipyretic Bristol-Myers Squibb 
Torrox MT Rofecoxib Antiinflammatory Torrent 
Valus Valdecoxib Antiinflammatory Glenmark 
Zelepar Selegiline Antiparkinson Elan Corporation 
Zofran ODT Ondansetron Antiemetic GlaxoSmithKline 
Zolpidem ODM Zolpidem tartarate Antipsychotic Bioavail 
Zomig ZMT Zolmitriptan Antimigraine Astra Zeneca 
Zotacet MD Cetrizine HCl Antiallergic Zota Pharma 
Zubrin Tepoxaline Canine NSAID Schering Corporation 
Zyprexa Zydis Olanzapine Antipsychotic Eli Lilly 
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1.2 Ideal properties of ODTs 
Below are the ideal properties of ODTs reported by some authors (Habib et al., 2000; 
Bradoo, 2001; Hirani et al., 2009).  The ODT should: 
? not require water to swallow, but it should dissolve or disintegrate in the mouth 
within a few seconds 
? leave minimal or no residue in the mouth after oral administration 
? have a smooth mouth feel and pleasant taste  
? be compatible with taste masking procedures and other excipients 
? have sufficient strength to withstand the rigours of the manufacturing process and 
post manufacturing handling 
? allow high drug loading 
? exhibit low sensitivity to environmental conditions such as humidity and 
temperature 
? be adaptable and amenable to existing processing and packaging machineries 
? be cost effective 
 
 
1.3 Advantages of ODTs 
 
The advantages of ODTs reported by some authors (Kuchekar et al., 2003; Shukla et 
al., 2009; Gupta et al., 2010; Sahoo et al., 2010) are listed below: 
 
? Ease of administration to the patients who cannot swallow, such as the elderly, 
stroke victims and bedridden patients; patients who should not swallow, such as 
renal failure patients and patients who refuse to swallow, such as paediatric, 
geriatric and psychiatric patients. 
? Improved compliance and administration convenience for travellers and busy 
people who do not have instant access to water. 
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? Pleasant taste and good mouth feel property of ODTs help to change the 
perception of medication as "bitter pill", particularly in paediatric patients due to 
improved taste of bitter drugs. 
? Convenience of administration and accurate dosing as compared to liquid 
formulations. 
? Ability to provide liquid medication advantages in the form of solid preparation. 
? Pregastric absorption of some drugs from mouth, pharynx and oesophagus as the 
saliva passes down to the stomach can result in improved bioavailability, reduced 
dose and improved clinical performance by reducing side effects. 
? Risk of choking or suffocation during administration of oral conventional tablets 
due to physical obstruction is avoided, thus providing improved safety. 
? Stability of drug is improved as compared to oral dosage forms like suspension, 
since the drug remains in solid dosage form till it is consumed. Hence, it 
combines the advantage of solid dosage form in terms of stability and liquid 
dosage form in terms of bioavailability. 
 
1.4 Disadvantages of ODTs  
A few authors (Aurora and Pathak, 2005; Bhowmik et al., 2009; Bharawaj et al., 
2010) reported that the application of ODT technology is limited by the following 
disadvantages: 
? Drugs with relatively larger doses are difficult to formulate into ODTs  
? Patients with Sjögren’s syndrome or dryness of the mouth due to decreased saliva 
production may not be good candidates for these tablet formulations. 
? The tablets may leave unpleasant taste and/or grittiness in the mouth if not 
formulated properly. 
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? Because they dissolve quickly, ODTs cannot provide controlled or sustained drug 
release, except those that contain slow-dissolving, microparticulate-coated drugs, 
which quickly disperse and are swallowed.  
? Fragile products require special unit-dose packaging, which may add to the cost. 
However, few technologies like Wowtab, Durasolv and AdvaTab can produce 
sufficiently hard and durable tablets to be packaged in multi-dose bottles. 
 
1.5 Challenges in the formulation of ODTs  
 
Hirani et al. (2009) and Bharawaj et al. (2010) described the challenges in the 
formulation of ODTs. Below are the summary of their report. 
 
1.5.1 Mechanical strength and disintegration time 
ODTs are formulated to obtain disintegration time usually within a minute. While 
doing so, maintaining a good mechanical strength is a prime challenge. Many ODTs 
are fragile and there is a chance of breakage during packing, transport or at the time 
of handling by the patients. Tablets prepared with technology like Zydis need special 
type of packaging. It is known that an increase in the mechanical strength will delay 
the disintegration time of the tablets. Hence, a good compromise between these two 
parameters is always essential. 
 
1.5.2 Taste masking  
Taste is one of the most important parameter governing patient compliance. At 
present many pharmaceutical drugs are bitter in taste. A tablet of bitter drug which 
disintegrate in the mouth will seriously affect patient compliance and acceptance of 
the dosage form. Hence, effective taste masking of the bitter drugs must be done 
before oral administration.  
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1.5.3 Mouth feel 
Mouth feel is critical and patients should receive a product that feels pleasant. An 
ODT should not disintegrate into larger particles; resulting in a gritty feeling in the 
mouth. An ODT should leave minimal or no residue in the mouth after oral 
administration. In some cases, addition of certain flavours and cooling agents like 
menthol can imbibe an improved mouth feel perception, resulting in a product that is 
perceived as being less gritty, even if the only change is the flavour.  
 
1.5.4 Sensitivity to environmental conditions  
The ODTs generally should exhibit low sensitivity to environment conditions such as 
humidity and temperature as most of the excipients used in an ODT preparation are 
meant to dissolve in minimum quantity of water. 
 
1.5.5 Cost 
The technology used for the preparation of an ODT should be acceptable in terms of 
cost of the finished product. Method like Zydis that require special technologies and 
specific packaging increase the cost to a remarkable extent. 
 
1.6 Patented technologies for ODTs 
Several pharmaceutical and drug delivery companies have patented and 
commercialized technologies to develop and market ODT products. A list of some 
patented technologies that produce commercial ODT products are summarized in 
Table 1.2. A brief description of some patented technologies is described below.  
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Table 1.2: List of patented technologies and their commercially available products. 
 
Patented 
technology 
Basis of 
technology Patent owner 
Active ingredient 
(Brand names) 
Zydis Lyophilization R.P.Scherer, Inc. 
Loratadine (Claritin 
Reditab and Dimetapp 
Quick Dissolve) 
Lyoc Lyophilization Farmalyoc 
Phloroglucinol Hydrate 
(Spasfon Lyoc) 
Piroxicam (Proxalyoc®) 
Loperamide 
(Loperamide-Lyoc®) 
Orasolv Direct compression Cima Labs, Inc. 
Paracetamol (Tempra 
Quicklets), Zolmitriptan 
(Zolmig Repimelt) 
Durasolv Direct compression Cima Labs, Inc. 
Hyoscyamine Sulfate 
(NuLev), Zolmitriptan 
(Zolmig ZMT) 
Wowtab Direct compression Yamanouchi Pharmatech, Inc. Famotidine (Gaster D) 
Flashdose Cottoncandy process 
Fuisz Technology 
Ltd. 
Tramadol HCl 
(Relivia Flash dose) 
Flashtab Direct compression Ethypharm Ibuprofen  (Nurofen FlashTab) 
AdvaTab Microcaps and diffuscap CR Eurand International 
AdvaTab cetrizine, 
AdvaTab paracetamol 
Oraquick Micromask taste masking KV Pharm. Co., Inc. 
Hyoscyamine sulfate 
ODT 
 
 
 
1.6.1 Zydis  
Zydis is the technology patented by R.P.Scherer. Zydis, the best known of the fast 
dissolving/disintegrating tablet preparations, was the first marketed new technology 
tablet. The procedure involved in the manufacturing of ODT using this technique is 
shown in Fig. 1.1. This process requires the active ingredient to be dissolved or 
dispersed in aqueous solution of water soluble structure formers. The resultant 
mixture is poured into the preformed blister packs of a laminate film. The trays 
holding the blister packs are passed through liquid nitrogen freezing tunnel to freeze 
the drug solution or dispersion and are subsequently loaded into a freeze dryer. After 
freeze-drying, the aluminium foil backing is applied on a blister sealing machine 
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(Kearney and Scherer, 2003). The Zydis dosage form and blister pack are shown in 
Fig. 1.2. 
 
 
Fig. 1.1: Schematic representation of manufacturing process involved in the Zydis 
technology (Kearney and Scherer, 2003). 
 
 
 
 
 
       
        Fig. 1.2: Zydis dosage form and blister pack (Kearney and Scherer, 2003). 
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Zydis formulation is a unique freeze dried tablet in which drug is physically 
entrapped or dissolved within the matrix of fast dissolving carrier material. 
Lyopilization results in preparations which are highly porous with a very high 
specific surface and disintegrates rapidly. When Zydis units are put into the mouth, 
the freeze-dried structure dissolves/disintegrates on the tongue in 2 to 3 sec and does 
not require water to aid swallowing (Kearney and Scherer, 2003; Goel et al., 2008). 
Few of the Zydis products are Claritin Reditab (Loratadine), Maxalt-MLT 
(Rizatriptan benzoate), Pepcid RPD (Famotidine), Zofran ODT (Ondansetron) and 
Zyprexa Zydis (Olanzapine). The Zydis matrix is composed of different materials. 
Polymers or structure formers such as gelatin, dextran or alginates are incorporated 
in the formulations to impart strength and resilience during handling of the tablets. 
These form a glossy amorphous structure which imparts strength. To obtain 
crystallinity, elegance and hardness, saccharides such as mannitol or sorbitol are 
incorporated. Water is used in the manufacturing process to ensure production of 
porous units to achieve faster disintegration while various gums are used to prevent 
sedimentation of dispersed drug particles in the manufacturing process. The Zydis 
formulation is also self preserving because the final water concentration in the freeze 
dried product is too low to allow microbial growth. The collapse protectants such as 
glycine are incorporated to prevent the shrinkage of Zydis units during freeze-drying 
process or on long-term storage (Bhowmik et al., 2009; Ratnaparkhi et al., 2009). 
The Zydis formulation utilizes flavours and sweeteners to optimize the taste of the 
dosage form. In addition, it also utilizes microencapsulation techniques with 
specialized polymers or complexation with ion exchange resins to mask the bitter 
taste of the drug (Prajapati et al., 2009). Zydis products are light weight and fragile 
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and must be packed in blister packs to protect the formulation from moisture in the 
environment and it may degrade at humidity greater than 65% (Bandari et al., 2008).  
 
The major advantage of the Zydis formulation is convenience in administration of 
the product. Due to dispersion and dissolution in saliva while still in the oral cavity, 
there can be a substantial amount of pregastric absorption (buccal, pharyngeal and 
gastric regions) from the Zydis product which can increase bioavailability of  some 
drugs compared to traditional tablets. The main disadvantages of this dosage form 
are they are relatively expensive and the production process is time consuming, 
fragility makes conventional packaging unsuitable for these products, difficult for the 
aged patients to handle because of inadequate strength, poor stability at higher 
temperatures and humidities and their limited ability to incorporate higher 
concentrations of active drug (Schiermeier and Schmidt, 2002; Prajapati et al., 2009).  
 
1.6.2 Lyoc  
Lyoc technology is patented by PHARMALYOC. Lyoc technology lyophilizes an 
aqueous solution, suspension, or emulsion of drug and excipients. Lyoc’s high 
degree of porosity yields shorter disintegration times (2 to 20 sec) than compressed 
tablets. Lyoc utilizes a freeze drying process but it differs from Zydis in that the 
product is frozen on the freeze dryer shelves. The liquid solution or suspension 
preparation evolves fillers, thickening agents, surfactant, non-volatile flavouring 
agents and sweeteners along with drug. This homogeneous liquid is prepared and 
placed directly into blister cavities followed by freeze drying. Non-homogeneity by 
sedimentation during freeze drying is avoided by incorporating a large proportion of 
undissolved inert filler (mannitol) to increase the viscosity of the emulsion. However, 
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the incorporation of high proportion of filler reduces the porosity of the tablets and as 
a result; the disintegration process becomes slower (Kearney and Scherer, 2003; 
Bandari et al., 2008; CIMA Labs, 2008; Wagh et al., 2010). 
 
1.6.3 Orasolv  
Orasolv technology is patented by CIMA Labs. The process includes use of 
effervescent disintegrating agents compressed with low pressure to produce the 
ODT. These prepared tablets disperse in the saliva in less than one minute with the 
aid of incorporated effervescent disintegrating agent (Bandari et al., 2008). The 
effervescent disintegrating pairs include an acid source (citric acid and tartaric acid) 
and a carbonate source (sodium bicarbonate and sodium carbonate); they release 
carbon dioxide gas as they come in contact with water (Wehling et al., 1993; Wagh 
et al., 2010). The unpleasant taste of a drug is not merely counteracted by sweeteners 
or flavours; both coating the drug powder and effervescence are means of taste 
masking in Orasolv. Conventional blenders and tablet machines are used to produce 
the tablets and the tablet has the appearance of a traditional compressed tablet. 
However, the mixture of drug and excipients are compressed at low pressure in order 
to decrease the disintegration time which yields a soft and brittle tablet in comparison 
with conventional tablets (Prajapati et al., 2009). For this reason, CIMA developed a 
special packaging system, Paksolv to protect tablets from breaking during transport 
and storage. The typical Paksolv package is shown in Fig. 1.3. It is a dome shaped 
blister package, prevents vertical movement of tablet with the depression and also 
offers light and moisture resistance (Amborn and Tiger, 2001; Bandari et al., 2008). 
An advantage with the low degree compression force of Orasolv is that the particle 
coating used for taste masking is not compromised by fracture during processing. 
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The products formulated with this technique are Tempra FirsTabs (Acetaminophen) 
and Remeron SolTab (Mirtazapine). 
 
 
Fig. 1.3: Typical Paksolv package (Pather et al., 2002).  
 
1.6.4 Durasolv  
Durasolv is the patented technology of CIMA Labs. The tablets produced by this 
technique are produced in a similar fashion to that of Orasolv but they have much 
higher mechanical strength due to application of higher compaction pressures during 
tableting. Tablets formulated by this technology consist of drug, non-direct 
compression filler (dextrose, mannitol, sorbitol, lactose and sucrose) and lubricant. 
Tablets are prepared using conventional tabletting equipment and have good rigidity. 
These tablets are so durable that they can be packed into either conventional 
packaging system like blisters or vials. Durasolv is an appropriate technology for low 
dose drugs. The limitations of this technique is its low drug loading capacity and 
high compaction pressure which are not suitable for incorporation of taste masked 
coated pellets. The coated pellets may be fractured during compaction, and the bitter-
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tasting drug may be exposed to the patient’s taste buds. Therefore, this technique is 
best suited for formulations containing relatively small doses of active ingredient 
(Khankari et al., 2000; Prajapati et al., 2009; Ratnaparkhi et al., 2009; Sahoo et al., 
2010; Wagh et al., 2010). The currently available products using this technology are 
NuLev (Hyosciamine sulphate) and Zomig ZMT (Zolmitriptan). 
 
1.6.5 Wowtab  
Wowtab technology is patented by Yamanouchi Pharmaceuticals. ‘Wow’ means 
“without water”. The Wowtab technology utilizes sugar and sugar-like (e.g., 
mannitol) excipients. This technology employs combination of low and high 
mouldability saccharides to produce ODT using conventional granulation and 
tableting methods. The combination of low (lactose, mannitol, glucose, sucrose and 
xylitol) and high mouldability saccharides (maltose, maltitol and sorbitol) is used to 
produce a rapidly melting tablet. When the low and high mouldable saccharides are 
used alone, the desired properties of hardness and quick disintegration cannot be 
achieved simultaneously, hence combinations are used. The active ingredient is 
mixed with low mouldability saccharides and granulated with high mouldability 
saccharides as binder and then compressed into tablet. Due to its significant 
hardness, the Wowtab formulation is a bit more stable to the environment than the 
Zydis or Orasolv. It is suitable for both conventional bottle and blister package 
(Venkateswara et al., 2000; Allen et al., 1998; Bandari et al., 2008; Bhowmik et al., 
2009; Prajapati et al., 2009; Wagh et al., 2010). Two Wowtab formulations currently 
in the US market are Benadyl Allery & Sinus FASTMELT (Diphenhydramine) and 
Children’s Benadyl Allergy & Cold FASTMELT (Diphenhydramine and 
Psuedoephedrine). 
 16
1.6.6 Flashdose 
Flashdose technology has been patented by Fuisz and is also known as shearform 
technology. Flashdose tablets consist of self-binding shearform matrix termed as 
“floss”. Shearform matrices are prepared by flash heat processing. This technology 
utilizes a unique spinning mechanism to produce a floss-like crystalline structure, 
much like cotton candy. The floss is a fibrous material commonly made of 
saccharides such as sucrose, dextrose, lactose and fructose at temperatures ranging 
between 180-250 °C. This crystalline sugar can then incorporate the active drug and 
be compressed into a tablet. The final product manufactured by this process is highly 
porous in nature. Hence, it disperses and dissolves quickly once placed onto the 
tongue and also offer very pleasant mouthfeel due to fast solubilization of sugars in 
presence of saliva. The characteristics of the product can be altered greatly by 
changing the temperature and other conditions during production. Instead of a floss-
like material, small spheres of saccharides can be produced to carry the drug. The 
process of making these microspheres is known as Ceform and it serves as an 
alternative method for taste masking of bitter drug (Myers et al., 1995; Fuisz, 1997; 
Agarwal et al., 2006; Wagh et al., 2010). Nurofen meltlet, a new form of ibuprofen 
as melt in mouth tablets was prepared using flashdose technology (Manivannan, 
2009; Shukla et al., 2009).  
 
1.6.7 Flashtab 
Flashtab technology is yet another fast dissolving/disintegrating oral tablet 
formulation. Prographarm laboratories have patented this technology. Tablet 
prepared by this system consists of an active ingredient in the form of microcrystals. 
The coacervation, microencapsulation and extrusion spheronisation techniques might 
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be used to prepare these drug microgranules. This technique utilizes conventional 
tableting technology and also used similar excipients as in conventional compressed 
tablets. The two types of excipients used in this technology are disintegrating agents 
(polyvinylpyrrolidone or carboxymethyl cellulose) and swelling agents 
(carboxymethyl cellulose, starch and microcrystalline cellulose). A combination of 
these two excipients is mixed with coated drug particles in this formulation to 
produce a tablet that disintegrates in the mouth within one minute (Cousin et al., 
1995; Bandari et al., 2008; Bhowmik et al., 2009). Nurofen Flashtab (Ibuprofen) was 
prepared by Ethypharm using this technique. 
 
 
1.6.8 Frosta  
 
Akina patented this technology. Frosta technology is based on the compression of 
highly plastic granules at low pressures to produce strong tablets with high porosity. 
The simplified manufacturing process of Frosta is shown in Fig. 1.4. The process to 
prepare highly plastic granules involves mixing porous plastic material with water 
penetration enhancer followed by granulating with binder. The components play an 
essential role in obtaining tablets with higher strength and faster disintegration due to 
porosity of the tablet than the other ODTs (Kaushik et al., 2004; Fu et al., 2005; 
Jeong et al., 2005; Wagh et al., 2010). 
 
Fig. 1.4: Manufacturing process of Frosta tablets. (API: Active Pharmaceutical 
Ingredient; Jeong et al., 2005).  
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1.6.9 AdvaTab 
Eurand International patented this technology. AdvaTab is distinct from other ODT 
technologies as it can be combined with Microcaps® taste masking technology and 
Diffucaps®, controlled release technology. The pairing of AdvaTab with Microcaps® 
creates products that offer the dual advantage of a patient preferred dosage form, 
together with a superior taste and smooth mouth feel. This is a critical advantage as 
the bitter or unpleasant taste of drugs is a significant restriction in the application of 
other ODT technologies. AdvaTab cetrizine and AdvaTab paracetamol were 
prepared with this technology (Prajapati et al., 2009; Shukla et al., 2009; Wagh et 
al., 2010). 
 
1.6.10 Oraquick  
This technology is patented by KV Pharmaceuticals. It utilizes a patented taste 
masking microsphere technology known as MicroMask®. In MicroMask® 
technology, taste masking process is performed by incorporating drug into matrix 
microspheres. The tablets are prepared by dissolving the sugar (sucrose, mannitol, 
sorbitol, xylose, dextrose or mannose) and protein (albumin or gelatin) in a suitable 
solvent such as water, ethanol, isopropyl alcohol and ethanol-water mixture. The 
solution of matrix is then spray dried to yield highly porous granules. The formed 
granules are then mixed with drug and other excipients and compressed at low 
compression force. The microspheres in the form of matrix protects drug which can 
be compressed with sufficient mechanical strength without disrupting taste-masking 
matrix. Lower heat of production than other fast disintegrating technologies makes 
Oraquick appropriate for heat sensitive drugs. KV Pharmaceuticals has products in 
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development such as analgesics, drugs for cough and cold, psychotropics and anti-
infectives (Bandari et al., 2008; Prajapati et al., 2009; Wagh et al., 2010). 
 
1.7 Manufacturing techniques for ODTs 
 
Many manufacturing techniques have been reported for the formulation of ODTs and 
a few techniques are discussed below. 
 
1.7.1 Freeze drying or lyophilization 
Freeze drying is a process in which water is sublimed from a frozen suspension or 
solution of drug with structure forming additives. Zydis and Lyoc are patented 
technologies involving this process to formulate ODTs. This technique allows drying 
of heat sensitive drugs and biologicals at low temperature under conditions that allow 
removal of water by sublimation. The drug is entrapped in a water soluble matrix 
which is freeze dried to produce a tablet with porous open matrix network. The 
resulting tablet absorbs saliva quickly when placed on the tongue and disintegrates 
into the lyophilized mass (Bandari et al., 2008; Shukla et al., 2009; Sahoo et al., 
2010). Other than active ingredient, the dosage form contains other excipients which 
increase the quality of final product as discussed in the Section 1.6.1. The 
researchers, Jaccard and Leyder (1985) used lyophilization technique to prepare an 
oral formulation that not only dissolved rapidly but also exhibited improved 
bioavailability for drugs like spironolactone and trolendomycin. Corveleyn and 
Remon (1997) and Ahmed et al. (2006) have formulated freeze dried tablets of 
hydrochlorthiazide and ketoprofen, respectively using this process. 
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1.7.2 Moulding 
In this technique, moulded tablets are prepared using water soluble ingredients so 
that the tablets disintegrate readily and dissolve rapidly. Moulding process is of three 
types i.e. compression moulding, heat moulding and vacuum evaporation without 
lyophilization (Dobetti, 2001; Wagh et al., 2010).  
 
Compression moulding process involves moistening the powder blend with a hydro 
alcoholic solvent followed by pressing at low pressures in moulded plates to form a 
wetted mass. The solvent is then removed by air-drying. The tablets manufactured in 
this manner are less compact than compressed tablets and possess a porous structure 
that accelerates disintegration/dissolution (Parakh and Gothoskar, 2003; Gupta et al., 
2010).  
 
The heat moulding process involves preparation of a suspension that contains a drug, 
agar and sugar (e.g. mannitol). The suspension is poured into the blister packaging 
wells; the agar solidifies at the room temperature to form a jelly and then drying is 
carried out at 30 °C under vacuum. In this process, agar solution can be used as a 
binder and the blister packaging well is used as a mould to manufacture the tablet 
(Masaki and Ban, 1995; Shukla et al., 2009).  
 
The vacuum evaporation without lyophilization process involves pouring of the drug 
excipient solution/suspension into a mould, freezing the mixture to form a solidified 
matrix and finally subjecting it to vacuum drying under a temperature within the 
range of its collapse temperature and equilibrium freezing temperature. This process 
results in the formation of partially collapsed matrix. This process differs from the 
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lyophilization technique, as in the former the evaporation of solvent occurs from a 
solid through the liquid phase to a gas under controlled conditions, instead of the 
sublimation which takes place in the latter process (Pebley et al., 1994).  
 
Tablets produced by moulding process are solid dispersions. Depending on the drug 
solubility in the carrier, the drug dissolves totally or partially to form a solid 
solution/dispersion in the carrier matrix. Moulded tablets possess porous structure, 
which facilitates rapid disintegration and dissolution. These tablets are associated 
with the problem of poor mechanical strength and they may undergo breakage or 
erosion during handling and opening of blister packs. However, the mechanical 
strength of moulded tablets is improved by adding binding agents such as sucrose, 
acacia or polyvinyl pyrrolidone (Manivannan, 2009; Shukla et al., 2009). Patel and 
Patel (2006) formulated valdecoxib fast dissolving tablets using this technique. 
 
1.7.3 Spray drying 
Spray drying technique is widely used in the pharmaceutical industry to produce 
highly porous and fine powders that dissolve rapidly. The processing solvent is 
evaporated rapidly by spray drying, which renders the product highly porous and 
thus can be used in manufacturing ODT. Allen and Wang (1996, 1997 and 2001) and 
Allen et al. (1998) produced a particulate support matrix (spray dried excipient base) 
for fast dissolving tablets by using a spray drying technique. The components in this 
matrix include hydrolyzed and non hydrolyzed gelatins, mannitol as a bulking agent, 
sodium starch glycolate or crosscarmellose or crospovidone as superdisintegrants and 
ethanol as volatilizing agent (Gupta et al., 2010). The surface tension of the droplets 
is further reduced by incorporating a volatilizing agent and therefore, more pores and 
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channels are created. To further accelerate disintegration and dissolution, acidic 
ingredient (citric acid) and/or alkaline ingredients (sodium bicarbonate) might be 
incorporated. The suspension of above excipients was spray dried to yield a porous 
powder which was compressed into tablets. The tablets showed rapid disintegration 
and enhanced dissolution. Tablets manufactured from the spray dried powder have 
been reported to disintegrate in less than 20 sec in aqueous medium (Bandari et al., 
2008; Bhowmik et al., 2009; Wagh et al., 2010). Mishra et al. (2006) prepared ODT 
tablets with Kollidon CL spray dried excipient base and direct compression 
technique and found that the minimum disintegration time and maximum drug 
release was observed with the former technique compared to the latter. 
 
1.7.4 Sublimation 
The key for rapid disintegration of ODTs is the presence of a porous structure in the 
tablet matrix. Conventional compressed tablets that contain highly water-soluble 
ingredients often fail to dissolve rapidly because of low porosity of the matrix. 
Hence, to generate a porous matrix, volatile ingredients are incorporated in the 
formulation that is later subjected to a process of sublimation. The steps involved in 
the sublimation process are depicted in Fig. 1.5. Inert solid ingredients with high 
volatility like ammonium bicarbonate, ammonium carbonate, benzoic acid, camphor, 
naphthalene, urea, urethane and phthalic anhydride may be compressed along with 
other excipients into tablets. This volatile material is then removed by sublimation 
leaving behind a highly porous matrix. Sublimation of these volatile materials from 
tablets results in faster disintegration and dissolution as compared with the tablets 
prepared from granules that were exposed to vacuum. Tablets manufactured by this 
technique have reported to be disintegrated in 10 to 20 sec. Solvents such as 
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cyclohexane and benzene were also suggested for generating the porosity in the 
matrix (Goel et al., 2008; Bhowmik et al., 2009; Gupta et al., 2010; Sahoo et al., 
2010). Makino et al. (1998) reported a method using water as a pore forming agent. 
Some authors successfully employed sublimation technique in preparation of fast 
disintegrating tablets (Koizumi et al., 1997; Roser and Blair, 1998; Lee et al., 2002; 
Patel and Patel, 2008; Kumar et al., 2009; Jeevanandham et al., 2010).  
 
 
Fig. 1.5: Schematic diagram of sublimation technique for preparation of ODTs. 
(Ratnaparkhi et al., 2009). 
 
 
 
1.7.5 Conventional methods 
The most important conventional methods used in formulating ODTs are wet 
granulation and direct compression techniques.   
 
 
Wet granulation technique is the most commonly used in tablet manufacture. It is the 
process of adding a liquid solution and usually a polymeric binder (polyvinyl 
pyrrolidone or starch) to the powdered starting materials to granulate. In most cases, 
water is used as a granulating liquid and in certain circumstances where water will 
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not wet the powder or active substance is unstable in the presence of water, organic 
solvents such as ethanol or isopropanol alone or in combination are used. This 
process is performed by mixer granulators and fluidized bed methods (Davies and 
Discovery, 2004). The process may involve the following steps: 
 
? Deagglomeration of the starting materials by milling or sieving 
? Dry mixing of the starting materials 
? Liquid addition and wet massing 
? Wet sieving to remove large lumps 
? Drying and sieving of the dried granules to achieve the desired size distribution. 
 
Different ODT formulations using wet granulation technique were reported by some 
authors (Gohel et al., 2004; Malke et al., 2007; Suresh et al., 2007; Mohapatra et al., 
2008; Jeevanandham et al., 2010).  
 
Direct compression represents the simplest and most cost effective tablet 
manufacturing technique. Direct compression is a process where the powder blend of 
the active ingredient and excipients are compressed on a tablet machine. There is no 
mechanical treatment of the powder apart from a mixing process. The mixture which 
is to be compressed must have good flow properties. Low manufacturing cost, usage 
of conventional equipments, commonly available excipients and a limited number of 
processing steps justify this as a first method of choice (Davies and Discovery, 2004; 
Ratnaparkhi et al., 2009). At present, this technique is widely applied in the 
preparation of ODTs because of the availability of improved excipients especially 
superdisintegrants and sugar based excipients. The detailed description of 
superdisintegrants and sugar based excipients are discussed in Section 1.9.  
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Several researchers formulated different ODT formulations using direct compression 
technique (Schiermeier and Schimdt, 2002; Mahajan et al., 2004; Patel and Patel, 
2006; Battu et al., 2007; Setty et al., 2008; Godge et al., 2009; Rangaswamy et al., 
2009; Keny et al., 2010).  
 
1.7.6 Mass extrusion 
This technology involves softening the active blend using the solvent mixture of 
water-soluble polyethylene glycol and methanol and subsequent expulsion of 
softened mass through the extruder or syringe to get a cylindrical shaped extrude 
which are finally cut into even segments using heated blade to form tablets. This 
process can also be used to coat granules of bitter drugs to mask their taste 
(Bhaskaran and Narmada, 2002; Shukla et al., 2009). Shishu et al. (2007) masked the 
intensely bitter taste of chlorpheniramine maleate by extrusion method. 
 
1.7.7 Nanonization 
This technique was invented by Elan Corporation. Nanomelt technology which 
involves the reduction of the active ingredient particle size to nano-size (<2000 nm) 
by various approaches such as wet milling, homogenisation, precipitation and 
supercritical fluid techniques has been reported. By reducing particle size, the 
specific surface area of the drug is increased. The nanoparticles are then stabilised 
against agglomeration by surface adsorption on selected stabilizers to maintain their 
reduced particle size. Then these nanoparticles are incorporated into ODTs. The 
result is a stable drug formulation that exhibits an increased dissolution rate. This 
technique is particularly advantageous for poorly water soluble drugs. Other 
advantages include fast disintegration/dissolution of nanoparticles leading to 
